» Articles » PMID: 28384049

Intestinal IgA As a Modulator of the Gut Microbiota

Overview
Journal Gut Microbes
Date 2017 Apr 7
PMID 28384049
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating evidence suggests that dysbiosis plays a role in the pathogenesis of intestinal diseases including inflammatory bowel disease (IBD) as well as extra-intestinal disorders. As a modulator of the intestinal microbiota, we isolated a mouse monoclonal IgA antibody (clone W27) with high affinities for multiple commensal bacteria, but not for beneficial bacteria such as Lactobacillus casei (L. casei). Via specific recognition of an epitope in serine hydroxymethyltransferase (SHMT), a bacterial metabolic enzyme, W27 IgA selectively inhibited the in vitro growth of bound bacteria, including Escherichia coli (E. coli), while having no effect on unbound beneficial bacteria such as L. casei. By modulating the gut microbiota in vivo, oral administration of W27 IgA effectively prevented development of colitis in several mouse models. Here we discuss how intestinal IgA modulates the gut microbiota through recognition of SHMT.

Citing Articles

From Dysbiosis to Disease: The Microbiome's Influence on Uveitis Pathogenesis.

Samalia P, Solanki J, Kam J, Angelo L, Niederer R Microorganisms. 2025; 13(2).

PMID: 40005638 PMC: 11857511. DOI: 10.3390/microorganisms13020271.


Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers.

Gao P, Morita N, Shinkura R Semin Immunopathol. 2024; 47(1):1.

PMID: 39567378 PMC: 11579142. DOI: 10.1007/s00281-024-01027-4.


Metabolic rewiring controlled by HIF-1α tunes IgA-producing B-cell differentiation and intestinal inflammation.

Meng X, Asadi-Asadabad S, Cao S, Song R, Lin Z, Safhi M Cell Mol Immunol. 2024; 22(1):54-67.

PMID: 39543372 PMC: 11686098. DOI: 10.1038/s41423-024-01233-y.


Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.

Takahashi K, Morita N, Tamano R, Gao P, Iida N, Andoh A J Gastroenterol. 2024; 59(9):812-824.

PMID: 38874761 PMC: 11339086. DOI: 10.1007/s00535-024-02121-y.


Gut dysbiosis impacts the immune system and promotes prostate cancer.

Shyanti R, Greggs J, Malik S, Mishra M Immunol Lett. 2024; 268:106883.

PMID: 38852888 PMC: 11249078. DOI: 10.1016/j.imlet.2024.106883.


References
1.
LINK A, Robison K, Church G . Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997; 18(8):1259-313. DOI: 10.1002/elps.1150180807. View

2.
Weiner J, Li L . Proteome of the Escherichia coli envelope and technological challenges in membrane proteome analysis. Biochim Biophys Acta. 2007; 1778(9):1698-713. DOI: 10.1016/j.bbamem.2007.07.020. View

3.
Hooper L, Littman D, Macpherson A . Interactions between the microbiota and the immune system. Science. 2012; 336(6086):1268-73. PMC: 4420145. DOI: 10.1126/science.1223490. View

4.
Renwick S, Snell K, Baumann U . The crystal structure of human cytosolic serine hydroxymethyltransferase: a target for cancer chemotherapy. Structure. 1998; 6(9):1105-16. DOI: 10.1016/s0969-2126(98)00112-9. View

5.
Chassaing B, Srinivasan G, Delgado M, Young A, Gewirtz A, Vijay-Kumar M . Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One. 2012; 7(9):e44328. PMC: 3434182. DOI: 10.1371/journal.pone.0044328. View